315 related articles for article (PubMed ID: 34505024)
1. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Dai L; Jin B; Liu T; Chen J; Li G; Dang J
EClinicalMedicine; 2021 Aug; 38():100990. PubMed ID: 34505024
[TBL] [Abstract][Full Text] [Related]
2. Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Chen DL; Li QY; Tan QY
J Thorac Dis; 2021 Jan; 13(1):220-231. PubMed ID: 33569202
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis.
Li S; Zhang H; Liu T; Chen J; Dang J
Front Oncol; 2021; 11():702924. PubMed ID: 34249764
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Kim JH; Kim HS; Kim BJ
Oncotarget; 2017 Nov; 8(54):93149-93155. PubMed ID: 29190984
[TBL] [Abstract][Full Text] [Related]
6. Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Hu X; Liu Y; He Y; Wang Z; Zhang H; Yang W; Lu J
J Oncol; 2022; 2022():3601942. PubMed ID: 35646119
[TBL] [Abstract][Full Text] [Related]
7. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
[TBL] [Abstract][Full Text] [Related]
9. Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients.
Xue C; Zheng S; Dong H; Lu X; Zhang X; Zhang J; Li J; Cui H
Front Oncol; 2021; 11():627016. PubMed ID: 34513654
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Raphael J; Batra A; Boldt G; Shah PS; Blanchette P; Rodrigues G; Vincent MD
Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
[TBL] [Abstract][Full Text] [Related]
11. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
Front Oncol; 2021; 11():732214. PubMed ID: 34557415
[TBL] [Abstract][Full Text] [Related]
12. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
Front Oncol; 2022; 12():795933. PubMed ID: 35223476
[TBL] [Abstract][Full Text] [Related]
13. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Liu T; Ding S; Dang J; Wang H; Chen J; Li G
J Thorac Dis; 2019 Jul; 11(7):2899-2912. PubMed ID: 31463119
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Liu Z; Xu T; Chang P; Fu W; Wei J; Xia C; Wang Q; Li M; Pu X; Huang F; Ge C; Gao Y; Gong S; Liu C; Dong L
Front Pharmacol; 2023; 14():1064227. PubMed ID: 36762107
[No Abstract] [Full Text] [Related]
15. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
Yang K; Li J; Bai C; Sun Z; Zhao L
Front Oncol; 2020; 10():1098. PubMed ID: 32733805
[No Abstract] [Full Text] [Related]
16. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
17. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang Y; Luo H; Zheng XL; Ge H
Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
[TBL] [Abstract][Full Text] [Related]
18. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.
Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y
Front Oncol; 2022; 12():968517. PubMed ID: 36439448
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
20. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
Front Oncol; 2022; 12():978069. PubMed ID: 36330494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
